Nasdaq
$2.90▼ 1.02%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $139.8MShares out 48.2M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
21- 10.13Pre-market26.10.10 07:30filedS-8Offering#●●●
JUPITER NEUROSCIENCES, INC.
Jupiter Neurosciences, Inc. has registered a total of 117,949 shares of common stock for issuance under its 2016, 2021, and 2025 equity incentive plans. This registration is intended for employee and director compensation, with an aggregate offering value of $287,795.56 based on a price of $2.44 per share.…more
$2.90-1.02%vs prev closeView filingShare
- 9.25Pre-market26.09.25 09:32filedS-3Offering
JUPITER NEUROSCIENCES, INC.
Jupiter Neurosciences, Inc. has filed a registration statement for the resale of 132,867 shares of common stock issued to PharmAla Biotech Holdings Inc. under a Strategic Asset License Agreement. This filing does not involve a new offering by the company, but rather facilitates the resale of shares by the selling stockholder. The company's independent auditors have included an explanatory paragraph in their reports regarding substantial doubt about the company's ability to continue as a going concern.…more
$2.90-1.02%vs prev closeView filingShare - 9.22Regular26.09.23 00:59SCHEDULE 13GOwnership
JUPITER NEUROSCIENCES, INC.
PharmAla Biotech Holdings Inc. has filed a SCHEDULE 13G, disclosing a beneficial ownership stake of more than 5% in Jupiter Neurosciences, Inc. This filing confirms the new acquisition of shares by PharmAla Biotech Holdings Inc.…more
$2.90-1.02%vs prev closeView filingShare
20 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.6Regular26.10.07 00:15#●●●#●●●
Jupiter Neurosciences Doses First Patient in Phase 2a Parkinson’s Trial and Explores Strategic Options…more
Jupiter Neurosciences has initiated dosing for the first patient in its Phase 2a RESET clinical trial for Parkinson’s disease. Concurrently, the company is exploring strategic alternatives, including potential sales or partnerships, to maximize shareholder value.…more
$2.90-1.02%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 8.21Regular26.08.22 01:22
●●●●●●●● ●●●●● ●●●●●●
Jupiter Neurosciences has entered into an agreement to sell 307,692 shares of common stock in a registered direct offering for approximately $2 million. This issuance is expected to result in shareholder dilution, which typically weighs on stock performance.…more
$2.90-1.02%vs prev closeShareBenzinga - 8.21Regular26.08.22 01:20
●●●●●●●● ●●●●● ●●●●●●
Jupiter Neurosciences has announced a registered direct offering of common stock to raise approximately $2 million in gross proceeds. The issuance of new shares may lead to shareholder dilution.…more
$2.90-1.02%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report